Feb 1, 2003

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease

Current Drug Targets
Debomoy K LahiriLon S Schneider


Alzheimer's disease (AD), a progressive, degenerative disorder of the brain, is believed to be the most common cause of dementia amongst the elderly. AD is characterized by the presence of amyloid deposits and neurofibrillary tangles in the brain of afflicted individuals. AD is associated with a loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning. AD appears to have a heterogeneous etiology with a large percentage termed sporadic AD arising from unknown causes and a smaller fraction of early onset familial AD (FAD) caused by mutations in one of several genes, such as the beta-amyloid precursor protein (APP) and presenilins (PS1, PS2). These proteins along with tau, secretases, such as beta-amyloid cleaving enzyme (BACE), and apolipoprotein E play important roles in the pathology of AD. On therapeutic fronts, there is significant research underway in the development of new inhibitors for BACE, PS-1 and gamma-secretase as targets for treatment of AD. There is also a remarkable advancement in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied an...Continue Reading

  • References
  • Citations82


  • We're still populating references for this paper, please check back later.

Mentioned in this Paper

Drug Development
Familial Alzheimer Disease (FAD)
Drug Delivery Systems
APP protein, human
Neurofibrillary Degeneration (Morphologic Abnormality)
Anti-Inflammatory Agents
Amyloid Beta Precursor Protein Measurement

About this Paper

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Alzheimer's Disease: APP

Amyloid precursor protein proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's Disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's Disease here.

Alzheimer's Disease: Abeta

Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with accumulation of amyloid plaques, which are comprised of amyloid beta. Here is the latest research in this field.

Related Papers

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Bao-gang Xu, Xun Wu
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
M S Parihar, Taruna Hemnani
© 2020 Meta ULC. All rights reserved